ESC 365 - How to improve cardiorenal outcomes in patients with CKD and T2D?

Open Access

How to improve cardiorenal outcomes in patients with CKD and T2D?

Session: Exploring the cardiorenal benefits of MR antagonism in CKD and T2D

Topic: Chronic Kidney Disease

Speaker: Doctor M. Senni (Bergamo, IT)

Sponsored by Bayer AG

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Michele Senni

Papa Giovanni XXIII Hospital, Bergamo (Italy)

46 presentations

1 follower

4 more presentations in this session

Welcome and introductions.

Speaker: Professor S. Anker (Berlin, DE)

Insights into the cardiovascular and kidney benefits of MR antagonism: Insights from theFIGARO-DKD and FIDELIO-DKD trials.

Speaker: Professor G. Filippatos (Athens, GR)

Live Q&A.

Summary and close.

Speaker: Professor S. Anker (Berlin, DE)

Access the full session

Exploring the cardiorenal benefits of MR antagonism in CKD and T2D

Speakers: Doctor M. Senni, Professor S. Anker, Professor G. Filippatos, Professor S. Anker

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by